跳至主要内容
临床试验/NL-OMON36971
NL-OMON36971已完成不适用

Single arm, open label, multi-centre intervention trial to evaluate the tolerance and acceptability of a high energy, nutrient enriched infant formula. - SATIN study

Danone Research - Centre for Specialised Nutrition0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 11(—)

入选标准

  • *Age 0 to 18 months (including 0 and 18 months)
  • *Currently receiving a high energy, nutrient enriched infant formula for at least 7 days prior to the baseline visit (day -2)
  • *Expected to require a high energy infant formula for at least 10 days after baseline visit
  • *Consuming, on average, at least 50% of their energy intake from the study feed
  • *Either enterally fed (nasogastric tube, gastrostomy, jejunostomy) or orally fed (bottle fed)
  • *Written informed consent from parents/ guardians that have legal custody of the child
  • *Parents/ guardians should have good knowledge of Dutch language

排除标准

  • *Infants less than 37 weeks gestation and requiring specific premature formula at the time of study entry
  • *Children between 12 and 18 months of age and with a body weight > 9kg that use Infatrini as sole source of nutrition
  • *Proven cow's milk allergy
  • *Lactose intolerance
  • *Galactosaemia
  • *Other medical or dietary contraindication to a polymeric, high energy, nutrient enriched infant formula (eg major hepatic or renal dysfunction)
  • *BMR vaccination performed within 14 days prior to baseline visit, any other vaccination performed within 48 hours prior to baseline visit or any vaccination planned within 10 days after baseline visit
  • *Any surgery planned within 10 days after baseline visit
  • *Investigator's uncertainty about the willingness or ability of the parent/caregiver to comply with the protocol requirements
  • *Participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

研究者

发起方
Danone Research - Centre for Specialised Nutrition

相似试验

尚未招募
不适用
Single arm, open label, multi-centre intervention trial to evaluate the tolerance and acceptability of a high energy, nutrient enriched infant formula.malnutrition, failure to thrive
NL-OMON27027Danone Research – Centre for Specialised Nutrition20
招募中
4 期
To Study the effect, safety, and tolerability of every 4 weekly administration of subcutaneous Mircera for treating renal anaemia in diabetic nephropathy patientsChronic kidney disease stages III-IV not on dialysis, not currently treated with ESA.
CTRI/2010/091/000580Roche Products India Pvt Ltd120
已完成
不适用
An Open Label, Multicentre, Multi-Dose, Single Arm Treatment Clinical Trial in Human Adult, Patients With Mild COVID-19.
CTRI/2021/05/033846Martin Sinclair BB Corp15
进行中(未招募)
1 期
Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)Atypical Haemolytic Uraemic Syndrome (aHUS)
EUCTR2017-003916-37-GBewcastle Upon Tyne Hospitals NHS Foundation Trust50
进行中(未招募)
1 期
Clinical study to evaluate the handling and safety of AVT06 PFS in subjects with chorioretinal vascular disease (ALVOEYE-D).chorioretinal vascular disease (neovascular age-related macular degeneration [nAMD], diabetic macular edema [DME], myopic choroidal neovascularization [CNV], retinal vein occlusion [RVO] and diabetic retinopathy [DR])MedDRA version: 20.1Level: PTClassification code: 10012689Term: Diabetic retinopathy Class: 100000004853MedDRA version: 20.0Level: PTClassification code: 10071129Term: Neovascular age-related macular degeneration Class: 100000004853MedDRA version: 20.0Level: PTClassification code: 10038907Term: Retinal vein occlusion Class: 100000004853MedDRA version: 20.1Level: LLTClassification code: 10057934Term: Diabetic macular edema Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10073711Term: Myopic choroidal neovascularization Class: 10015919
CTIS2023-505225-13-00Alvotech Swiss AG35